← Back to Search

MRI and MRS Brain Scans for Brain Mapping in Healthy Subjects

N/A
Recruiting
Led By Steve Li, Ph.D.
Research Sponsored by National Institute of Mental Health (NIMH)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18-65 years of age
Be older than 18 years old
Must not have
History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson's disease, seizure disorder or traumatic brain injury
Timeline
Screening 3 weeks
Treatment Varies
Follow Up prospective and ongoing
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking for healthy individuals to participate in a study involving magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) scans of the brain to help researchers develop new techniques for evaluating brain activity and chemistry.

Who is the study for?
This trial is for healthy individuals aged 18 to 65 who can consent and lie flat for about two and a half hours. It's not suitable for those with significant lab abnormalities, pregnant or breastfeeding women, people with metallic implants affected by MRI, claustrophobia, HIV positive individuals, substance use disorders, current psychiatric diagnoses or neurological conditions.
What is being tested?
The study aims to improve brain imaging techniques using magnetic resonance imaging (MRI) and spectroscopy (MRS). Participants will undergo medical exams followed by an MRI scan of the brain and MRS scans to view and measure brain chemicals.
What are the potential side effects?
Since this trial involves standard MRI/MRS procedures without drugs or invasive treatments, side effects are minimal but may include discomfort from lying still during the scan or anxiety in enclosed spaces.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have a history of major neurological illnesses like MS, Parkinson's, seizures, or brain injuries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~prospective and ongoing
This trial's timeline: 3 weeks for screening, Varies for treatment, and prospective and ongoing for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The is the quality of the MR spectroscopy which includes spectrum signal-to-noise (SNR) ratio, spectral lineshape, linewidth, and resolution.
Secondary study objectives
The is the performance improvements of the scanner hardware, software and methodology.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: One ArmExperimental Treatment2 Interventions
Subjects receive the same scan

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)Lead Sponsor
2,914 Previous Clinical Trials
2,738,275 Total Patients Enrolled
3 Trials studying Brain Mapping
3,346 Patients Enrolled for Brain Mapping
Steve Li, Ph.D.Principal InvestigatorNational Institute of Mental Health (NIMH)
1 Previous Clinical Trials
200 Total Patients Enrolled
Li An, Ph.D.Principal InvestigatorNational Institute of Mental Health (NIMH)
1 Previous Clinical Trials
200 Total Patients Enrolled

Media Library

One Arm Clinical Trial Eligibility Overview. Trial Name: NCT01266577 — N/A
Brain Mapping Research Study Groups: One Arm
Brain Mapping Clinical Trial 2023: One Arm Highlights & Side Effects. Trial Name: NCT01266577 — N/A
One Arm 2023 Treatment Timeline for Medical Study. Trial Name: NCT01266577 — N/A
~4 spots leftby Jan 2025